Merit Financial Group
CRL icon

Merit Financial Group’s Charles River Laboratories CRL Stock Holding History

Merit Financial Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$519K Buy
1,758
+251
+17% +$66.2K ﹤0.01% 1550
2026
Q2 		$342K Buy
+1,507
New +$268K ﹤0.01% 1735

Other funds holding CRL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Cooke & Bieler
Cooke & Bieler Philadelphia, Pennsylvania $6.36B AUM 0.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Van Berkom & Associates
Van Berkom & Associates Montreal, Quebec, Canada $2.81B AUM 6.02% 1-Year Est. Return
Boston Trust Walden
Boston Trust Walden Boston, Massachusetts $12.4B AUM 21.62% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Merit Financial Group's CRL Position: Q3 2026 in Review

Merit Financial Group increased its Charles River Laboratories (CRL) stake by 17% in Q3 2026, buying an estimated $66.2K and bringing the position to 1,758 shares worth $519K. The position accounts for ﹤0.01% of the portfolio, ranked #1550.

Merit Financial Group first reported a position in CRL in Q2 2026 and has held it in 2 quarters since. 285 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Merit Financial Group held 1,758 shares of Charles River Laboratories worth $519K as of Q3 2026.
  • Merit Financial Group bought 251 Charles River Laboratories shares in Q3 2026, an estimated $66.2K.
  • Charles River Laboratories made up ﹤0.01% of Merit Financial Group's portfolio in Q3 2026, its #1550 holding.
  • Merit Financial Group first reported a position in Charles River Laboratories in Q2 2026 and has held it in 2 quarters since.
  • 285 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Merit Financial Group's 13F filing for Q3 2026, filed 6 Nov 2026.